Probiotics in the treatment of inflammatory intestine diseases in children


Cite item

Full Text

Abstract

The development of inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and nonspecific ulcerative colitis, is associated with disruption of the interaction of the intestinal microbiota and the intestinal immune system. Taking into account the beneficial effect of probiotics on the protective intestinal barrier and the formation of immunological tolerance, these drugs can be used for the treatment of IBD. Only few reports were dedicated to this problem in children. Results of the study of effectiveness of Saccharomyces boulardii (Enterol) in remission maintenance in children with CD are presented. Twenty-four children after remission induction were randomized into 2 equal groups. The patients of group 1 have received maintenance therapy with mesalazine (50 mg/kg), and patients of group 2 in addition to this therapy received Enterol (500 mg / day) within first 3 months of treatment. Dynamics of clinical presentation and the contents of calprotectin in feces were evaluated 6 months after treatment. The exacerbation was observed in 8.3% of children receiving Enterol, and in 25% of children not receiving this drug. Level of calprotectin in feces was significantly lower in patients receiving Enterol.

References

  1. Swidsinski A, Ladhoff A, Pemthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
  2. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-274.
  3. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
  4. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
  5. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.Aliment Pharmacol Ther 2003;17:509-15.
  6. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003;38:409-14.
  7. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
  8. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
  9. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 999;354:635-639.
  10. Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260-3.
  11. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8.
  12. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli reparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
  13. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
  14. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
  15. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.Aliment Pharmacol Ther 1999;13:1103-8.
  16. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31:453-457.
  17. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gasroenterol 2004;4:5.
  18. Bousvaros A, Guandalini S, Baldassano RN, et al. A ranomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11:833-39.
  19. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-409.
  20. Plein K, Hotz J. Therapeutic effects of Saccharamyces boulardii on mild residual symptoms in stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. J Gasroenterol 1993;31:129-134.
  21. Guslandi M, Mezzi G, Sorghi M, et al.Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-4.
  22. Czerucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68:5998-6004.
  23. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorragic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003; 71: 766-773.
  24. Czerucka D, Dahan S, Mograbi B, et al. Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 2001; 69: 1298-1305.
  25. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-97.
  26. Ruemmelle FM, Bier D, Marteau P, et al. Clinical evidence of immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009; 48(2):126-141.
  27. Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS ONE 2007;2:313.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies